

Clinical Trials Summary for out of hours Important Reference



**Lancashire Teaching
Hospitals**
NHS Foundation Trust

Acronym study title	<p>ASTELLA/HIGHLIGHTS study IRAS number 1010129</p> <p>A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women with Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy</p>
Study Details	<p>Oral drug called fezolinetant or placebo taken daily for approximately 52 weeks. It is a small-molecule, selective neurokinin-3 receptor antagonist. Prescribed on iQemo. Patient attends clinic monthly and issued with tablets if PI/SubI gives go ahead.</p>
Principal Investigator PI Sub PI's	<p>Name: Dr Martin Hogg Contact: 01772 522699 / martin.hogg@lthtr.nhs.uk Address: Lancashire Teaching Hospitals NHS Foundation Trust, Rosemere Cancer Centre, Royal Preston Hospital, Sharoe Green Lane, Preston, Lancashire, PR2 9HT</p>
Research Nurse Team	<p>Amanda Cook Contact 01772 524656</p>
Drug therapy	<p>Oral drug called fezolinetant or placebo taken daily for approximately 52 weeks. It is a small-molecule, selective neurokinin-3 receptor antagonist.</p>
In the event that a patient calls this hotline for advise	<p>Common side effects Diarrhoea Insomnia Increase of ALT AST Stomach Pain</p> <p>Trial notes are kept in the medical notes, EVOLVE and iQemo system for reference.</p> <p>Please advise patients to keep their trial documentation on their person when attending hospital for review.</p>